How ICH Stability Guidelines Differ for Biologics vs. Small Molecules
In pharmaceutical development, understanding how stability testing requirements differ between biologics and small molecule drugs is crucial for regulatory compliance. While both product types must meet ICH stability expectations, their testing parameters, degradation risks, and documentation differ significantly. This tutorial-style guide highlights the practical distinctions between ICH guidelines like Q1A and Q5C, with a focus…
Read More “How ICH Stability Guidelines Differ for Biologics vs. Small Molecules” »
